https://www.fool.com/investing/general/2013/02/18/mercks-weakest-blockbuster.aspx
https://www.fool.com/investing/general/2013/03/09/this-week-in-health-reform.aspx
https://www.fool.com/investing/general/2013/02/04/a-pcsk9-contender-partners-up.aspx
https://www.fool.com/investing/general/2012/12/27/3-things-to-watch-at-merrimack.aspx
https://www.fool.com/investing/general/2013/02/07/takeover-rumors-surround-this-drug-stock.aspx
https://www.fool.com/investing/general/2013/03/13/better-health-an-iphone-app-away.aspx
https://www.fool.com/investing/general/2012/11/06/5-companies-dominating-diabetes.aspx
https://www.fool.com/investing/general/2013/04/10/what-will-obamacare-do-to-medicare.aspx
https://www.fool.com/investing/general/2013/04/02/obamacare-falls-into-place-and-health-insurers-rej.aspx
https://www.fool.com/investing/general/2012/12/18/1-way-to-jazz-up-this-pharma-stock.aspx
https://www.fool.com/investing/general/2013/02/04/sanofis-new-diabetes-play-moves-forward.aspx
https://www.fool.com/investing/general/2012/12/26/3-drug-disappointments-from.aspx
https://www.fool.com/investing/general/2013/01/22/whats-ahead-for-affymax.aspx
https://www.fool.com/investing/general/2012/11/27/3-things-to-watch-at-exelixis.aspx
https://www.fool.com/investing/general/2013/03/28/obamacare-is-changing-health-insurance-forever.aspx
https://www.fool.com/investing/general/2013/01/18/3-things-to-watch-at-alkermes.aspx
https://www.fool.com/investing/general/2012/11/05/3-things-to-watch-with-biomarin.aspx
https://www.fool.com/investing/general/2012/11/13/can-ariad-survive-on-2-drugs.aspx
https://www.fool.com/investing/general/2013/01/07/3-health-care-companies-im-watching-today.aspx
https://www.fool.com/investing/general/2012/12/20/3-things-to-watch-at-isis-pharmaceuticals.aspx
https://www.fool.com/investing/general/2013/02/14/why-regeneron-shares-dropped-today.aspx
https://www.fool.com/investing/general/2013/03/25/is-your-state-embracing-obamacare.aspx
https://www.fool.com/investing/general/2013/02/28/mercks-hpv-growth-continues.aspx
https://www.fool.com/investing/general/2013/01/31/who-will-win-this-small-drug-market.aspx
https://www.fool.com/investing/general/2013/01/10/biomarins-big-week.aspx
https://www.fool.com/investing/general/2012/11/05/arenas-pipeline-problems.aspx
https://www.fool.com/investing/general/2013/02/25/whats-next-for-dynavax.aspx
https://www.fool.com/investing/general/2012/12/05/3-things-to-watch-at-lexicon.aspx
https://www.fool.com/investing/general/2013/02/14/mercks-dynamic-duo.aspx
https://www.fool.com/investing/general/2013/03/08/does-this-change-the-medicaid-expansion-game.aspx
https://www.fool.com/investing/general/2013/03/21/why-cardinal-health-dropped.aspx
https://www.fool.com/investing/general/2013/01/11/jpmorgan-healthcare-conference-rewind-rigel-pharma.aspx
https://www.fool.com/investing/general/2012/11/21/big-pharmas-safest-diabetes-play.aspx
https://www.fool.com/investing/general/2012/12/11/report-700000-of-gold-dust-missing-from-pfizer-lab.aspx
https://www.fool.com/investing/general/2013/03/30/3-health-care-stories-you-missed-this-week.aspx
https://www.fool.com/investing/general/2013/02/20/sanofis-glp-1-accepted-for-review-by-fda.aspx
https://www.fool.com/investing/general/2013/02/12/mercks-crash-of-a-titan.aspx
https://www.fool.com/investing/general/2013/04/08/isis-big-pharmas-little-friend.aspx
https://www.fool.com/investing/general/2012/11/16/this-top-dollar-drug-hits-the-discount-rack.aspx
https://www.fool.com/investing/general/2012/12/31/the-top-pharma-acquisitions-of.aspx
https://www.fool.com/investing/general/2013/03/05/can-health-insurance-still-profit-from-baby-boomer.aspx
https://www.fool.com/investing/general/2013/02/13/why-seattle-genetics-dropped.aspx
https://www.fool.com/investing/general/2012/12/05/3-things-to-watch-at-nps-pharmaceuticals.aspx
https://www.fool.com/investing/general/2012/11/08/does-amarin-need-the-fda-to-play-nce.aspx
https://www.fool.com/investing/general/2013/02/19/will-isis-right-pfizers-wrong.aspx
https://www.fool.com/investing/general/2013/03/12/old-sick-and-poor-health-cares-most-expensive-pati.aspx
https://www.fool.com/investing/general/2012/11/01/3-things-to-watch-with-sarepta-therapeutics.aspx
https://www.fool.com/investing/general/2013/04/05/3-obamacare-stories-you-missed-this-week.aspx
https://www.fool.com/investing/general/2013/01/04/abbvies-born-what-now.aspx
https://www.fool.com/investing/general/2013/02/20/mercks-low-cholesterol.aspx
https://www.fool.com/investing/general/2013/01/03/another-als-drug-failure-for-the-pile.aspx
https://www.fool.com/investing/general/2012/12/13/1-catalyst-biotech-investors-need-to-watch-2.aspx
https://www.fool.com/investing/general/2012/12/29/top-alzheimers-missteps-of.aspx
https://www.fool.com/investing/general/2012/11/14/who-will-pioneer-the-new-diabetes-market.aspx
https://www.fool.com/investing/general/2013/01/28/statins-beware.aspx
https://www.fool.com/investing/general/2013/01/16/whats-ahead-for-ariad.aspx
https://www.fool.com/investing/general/2013/01/29/whats-in-regenerons-pipes.aspx
https://www.fool.com/investing/general/2012/11/29/this-drug-helps-investors-rest-easy.aspx
https://www.fool.com/investing/general/2013/03/25/why-this-hospital-and-health-insurer-dropped.aspx
https://www.fool.com/investing/general/2013/04/01/sizing-up-one-of-obamacares-biggest-players.aspx
https://www.fool.com/investing/general/2013/02/28/a-drug-thats-ready-to-lose.aspx
https://www.fool.com/investing/general/2012/11/02/3-things-to-watch-with-seattle-genetics.aspx
https://www.fool.com/investing/general/2013/03/15/this-weeks-health-care-reform-headlines.aspx
https://www.fool.com/investing/general/2013/03/25/3-health-care-stories-you-probably-missed.aspx
https://www.fool.com/investing/general/2013/04/09/top-obamacare-questions-answered.aspx
https://www.fool.com/investing/general/2013/01/09/vertex-the-year-ahead.aspx
https://www.fool.com/investing/general/2013/04/16/allergan-waits-to-exhale.aspx
https://www.fool.com/investing/general/2012/11/13/is-this-diabetes-drug-mercks-next-blockbuster.aspx
https://www.fool.com/investing/general/2012/11/19/3-things-to-watch-with-nektar-therapeutics.aspx
https://www.fool.com/investing/general/2013/04/18/3-obamacare-lessons-from-medicaid-expansion.aspx
https://www.fool.com/investing/general/2013/02/16/does-the-arthritis-market-have-growing-pains.aspx
https://www.fool.com/investing/general/2013/01/31/whats-ahead-for-exelixis.aspx
https://www.fool.com/investing/general/2012/12/14/aegerion-52-week-high.aspx
https://www.fool.com/investing/general/2013/01/23/map-gets-inhaled-by-allergan.aspx
https://www.fool.com/investing/general/2012/12/31/vivus-wraps-up-pivotal-year.aspx
https://www.fool.com/investing/general/2013/01/25/a-late-stage-threshold-for-success.aspx
https://www.fool.com/investing/general/2013/02/25/elan-not-keen-on-royalty-pharmas-66-billion-offer.aspx
